Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline

Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.

Assess your knowledge with this case based self-assessment. Each question includes a detailed answer discussion.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to a maximum of 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile

Review & Edit your Profile

Target Audience

Physicians and healthcare professionals treating older adults with diabetes.

Learning Objectives

The objective is to formulate clinical practice guidelines for the treatment of diabetes in
older adults.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
03/23/2019
Course expires: 
03/31/2020
Rating: 
0

Derek LeRoith, MD, Chair
Mount Sinai Medical Center

Susan Braithwaite, MD
Presence Saint Francis Hospital

Boris Draznin, MD, PhD
University of Colorado

Marie McDonnell, MD
Brigham and Women's Hospital

Mark Molitch, MD
Northwestern University

Alan Sinclair, MSc, MD
University of Aston, United Kingdom

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s task force for this guideline.  

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationship(s): Derek LeRoith, MD is a consultant for Astra Zeneca and MannKind. He is faculty for Merck Sharp & Dohme Corporation. Mark Molitch, MD is a consultant for Janssen Global Services, Chiasma, Merck and Novartis. Her is also a DSMB member for Merck and Pfizer. His souse own stock in Amgen. Dr. Molitch's institution receives research funds from Bayer, Novo Nordisk, Calibra, Chiasma, and Novartis. Alan Sinclair, MSc, MD is a speaker for Eli Lilly and is on the advisory board for Merck Sharp and Dohme. Dr. Sinclair's institution received sponsorship funds from Merck Sharp and Dohme/Merck.

The following faculty reported no relevant financial relationships: Susan Braithwaite, MD; Boris Draznin, MD, PhD; Marie McDonnell, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:
The educational content in this enduring activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.  

DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.  

PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.  

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is not supported by educational grant(s) or other funds from any commercial supporter. 

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.  The Endocrine Society designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to a maximum of 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation

Accreditation Period

Course opens: 
03/23/2019
Course expires: 
03/31/2020

This course is complimentary and available to everyone. Please click START to enroll and begin. To claim CME, you must be logged in. If you already have an account please login. If you do not have an account, you may create a complimentary account on the login page.